This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Why Is Abivax Stock Trading Higher On Monday? Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns.
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area.
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings reports. Robinhood Markets (
NASDAQ: HOOD ) and AppLovin (
NASDAQ: APP ) are making headlines with their impending entry into the benchmark S&P 500 index,
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile.
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket Shares of Vicor Corporation (
NASDAQ:VICR ) rose sharply in pre-market trading after posting second-quarter results.
